72 results on '"Atas, N."'
Search Results
2. AB1189 THE CIRCULATING LEVELS OF ENDOGENOUS EICOSAPENTAENOIC ACID AND DOCOSAHEXAENOIC ACID-DERIVED RESOLVINS ARE INCREASED IN SYSTEMIC SCLEROSIS: EVIDENCE FROM A SINGLE CENTRE COHORT
3. AB1317 SERUM INTERLEUKIN 37 LEVELS IN FAMILIAL MEDITERRANEAN FEVER PATIENTS AND ASSOCIATION WITH CLINICAL FEATURES
4. THE IMPACT OF TUMOUR NECROSIS FACTOR-ALPHA INHIBITOR TREATMENT ON WNT SIGNALING INHIBITORS, NOGGIN AND CYTOKINE LEVELS IN AXIAL SPONDYLOARTHRITIS
5. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients
6. POS0940 THE IMPACT OF TUMOUR NECROSIS FACTOR-ALPHA INHIBITOR TREATMENT ON WNT SIGNALING INHIBITORS, NOGGIN AND CYTOKINE LEVELS IN AXIAL SPONDYLOARTHRITIS
7. INACTIVITY BEHAVIOR AND EXERCISE BARRIERS IN PATIENTS WITH BEHCET'S DISEASE
8. CYCLOPHOSPHAMIDE VS AZATHIOPRINE FOR THE TREATMENT OF CONNECTIVE TISSUE RELATED INTERSTITIAL LUNG DISEASE
9. TEMPORAL CHANGES IN LUNG NODULES DETECTED IN INDIVIDUALS WITH RHEUMATOID ARTHRITIS WITH BIOLOGIC DMARD TREATMENTS
10. VISIT COMPLIANCE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM A GAZI UNIVERSITY FMF COHORT
11. COLCHICINE INTOLERANCE IN FMF PATIENTS AND PRIMARY OBSTACLES FOR OPTIMAL DOSING
12. THE EFFECTS OF CLINICAL PILATES EXERCISES IN PATIENTS WITH RHEUMATOID ARTHRITIS
13. ASSESMENT OF THE PHYSICAL ACTIVITY IN SYSTEMIC SCLEROSIS PATIENTS BY USING COMMERCIAL SMART BANDS AND ITS ASSOCIATION WITH DISEASE CHARACTERISTICS: A PILOT STUDY
14. FRI0109 TEMPORAL CHANGES IN LUNG NODULES DETECTED IN INDIVIDUALS WITH RHEUMATOID ARTHRITIS WITH BIOLOGIC DMARD TREATMENTS
15. SAT0509 MYCOPHENOLATE MOFETIL VERSUS AZATHIOPURINE FOR THE MAINTENANCE TREATMENT OF CONNECTIVE-TISSUE RELATED INTERSTITIAL LUNG DISEASE FOLLOWING CYCLOPHOSPHAMIDE TREATMENT
16. AB1013 CYCLOPHOSPHAMIDE VS AZATHIOPRINE FOR THE TREATMENT OF CONNECTIVE TISSUE RELATED INTERSTITIAL LUNG DISEASE
17. AB0548 ASSESMENT OF THE PHYSICAL ACTIVITY IN SYSTEMIC SCLEROSIS PATIENTS BY USING COMMERCIAL SMART BANDS AND ITS ASSOCIATION WITH DISEASE CHARACTERISTICS: A PILOT STUDY
18. FRI0507 COLCHICINE INTOLERANCE IN FMF PATIENTS AND PRIMARY OBSTACLES FOR OPTIMAL DOSING
19. THU0289 PREDICTORS AND SEVERITY OF POST-THROMBOTIC SYNDROME IN VASCULAR BEHÇET’S DISEASE: RETROSPECTIVE MULTICENTER STUDY
20. AB1306-HPR THE EFFECTS OF CLINICAL PILATES EXERCISES IN PATIENTS WITH RHEUMATOID ARTHRITIS
21. AB1065 VISIT COMPLIANCE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: RESULTS FROM A GAZI UNIVERSITY FMF COHORT
22. SAT0620-HPR INACTIVITY BEHAVIOR AND EXERCISE BARRIERS IN PATIENTS WITH BEHÇET’S DISEASE
23. FRI0283 CO-MEDICATION WITH CSDMARD HAS LITTLE EFFECT ON THE RETENTION OF TNF INHIBITORS IN PSORIATIC ARTHRITIS, RESULTS FROM THE EUROSPA COLLABORATION
24. Treatment of anti-TNF-related paradoxic palmoplantar psoriasis in Behcet's disease with azathioprine
25. RELATIONSHIP BETWEEN THORACIC KYPHOSIS AND SHOULDER MUSCLE STRENGTH AND SHOULDER JOINT MOTION IN MALE PATIENTS WITH ANKYLOSING SPONDYLITIS
26. SLEEP QUALITY IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS SHOULD BE KEPT IN MIND
27. THE PREVALENCE OF SPONDYLOARTHROPATHY IN PATIENTS WITH TAKAYASU ARTERITIS
28. ON DEMAND USE OF ANAKINRA FOR THE ATTACKS OF FAMILIAL MEDITERRANEAN FEVER (FMF)
29. Frequency, characteristics, and clinical determinants of ‘prodrome’ in familial Mediterranean fever patients
30. Chronic inflammation in adult familial Mediterranean fever patients: underlying causes and association with amyloidosis
31. Frequency, characteristics, and clinical determinants of 'prodrome' in familial Mediterranean fever patients.
32. THU0172 Sleep quality in elderly patients with rheumatoid arthritis should be kept in mind
33. THU0620 On demand use of anakinra for the attacks of familial mediterranean fever (FMF)
34. SAT0611 Canakinumab use in adult familial mediterranean fever patients: a large single centre experience
35. THU0433 The prevalence of spondyloarthropathy in patients with takayasu arteritis
36. THU0606 Effect of interleukin-1 antagonists on the quality of life in familial mediterranean fever patients
37. Peritoneal dialysis
38. Duration of anti-TNF treatment in vascular Behçet's disease: better to prolong treatment?
39. Assessment of venous disease with different venous disease specific scales in Behçet's disease patients with deep vein thrombosis.
40. Successful treatment of aggressive AA amyloidosis with tocilizumab in a patient with polymyalgia rheumatica.
41. Editorial: Radiographic progression in axial spondyloarthritis.
42. The impact of anti-TNF treatment on Wnt signaling, noggin, and cytokine levels in axial spondyloarthritis.
43. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
44. Predictors for the risk and severity of post-thrombotic syndrome in vascular Behçet's disease.
45. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
46. Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists.
47. BTD Gene Mutations in Biotinidase Deficiency: Genotype-Phenotype Correlation.
48. Response to Anakinra in 3 Patients With Erosive Osteoarthritis.
49. Predictors of persistent inflammation in familial Mediterranean fever and association with damage.
50. Factors associated with damage in patients with familial Mediterranean fever.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.